Argus Lowers Abbott Laboratories (NYSE:ABT) Price Target to $140.00

Abbott Laboratories (NYSE:ABT) had its target price lowered by equities researchers at Argus from $150.00 to $140.00 in a research report issued to clients and investors on Tuesday,MarketScreener reports. Argus’ price target indicates a potential upside of 31.99% from the company’s previous close.

Other equities analysts have also issued reports about the stock. Barclays upped their price objective on shares of Abbott Laboratories from $162.00 to $169.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Raymond James Financial lowered their price target on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Mizuho boosted their price objective on Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, October 14th. William Blair raised Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Finally, Oppenheimer reduced their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.75.

Abbott Laboratories Trading Down 2.0%

Shares of Abbott Laboratories stock opened at $106.07 on Tuesday. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $141.23. The firm’s 50-day moving average price is $123.50 and its 200 day moving average price is $127.80. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $184.44 billion, a PE ratio of 28.51, a P/E/G ratio of 1.72 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the business posted $1.34 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. IMG Wealth Management Inc. raised its holdings in Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new stake in Abbott Laboratories in the fourth quarter valued at $27,000. Cloud Capital Management LLC acquired a new position in Abbott Laboratories in the third quarter valued at $29,000. Guerra Advisors Inc purchased a new position in shares of Abbott Laboratories during the third quarter worth about $31,000. Finally, Anfield Capital Management LLC increased its position in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.